Beta-2 agonists are bronchodilators commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Although beta-2 agonists have been associated with a reduced risk of Parkinson’s disease in some previous epidemiological studies, this association was not found in a recent register-based study from the University of Eastern Finland.
Merck winds down Phase 3 TIGIT/PD-1 combo study due to safety-related dropouts
A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its anti-TIGIT drug vibostolimab in
May 14, 2024